According to Advanced Cardiovascular Life Support (ACLS) guidelines, what is the first‑line medication for unstable bradycardia and what is its dosing regimen?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

First-Line Drug for Unstable Bradycardia According to ACLS Guidelines

Atropine is the first-line drug for unstable bradycardia, dosed at 0.5 to 1 mg IV, repeated every 3 to 5 minutes as needed, up to a maximum total dose of 3 mg. 1, 2

Dosing Algorithm

Initial dose: Start with 0.5 to 1 mg IV push

  • Repeat dosing: If bradycardia persists with ongoing signs of instability, give additional 0.5 to 1 mg doses every 3 to 5 minutes
  • Maximum cumulative dose: 3 mg total (some guidelines cite 1.5 to 3 mg range) 1, 2
  • Avoid doses <0.5 mg: These may paradoxically worsen bradycardia through a parasympathomimetic effect 3, 2

Recent evidence suggests that 1 mg initial doses may be more effective than 0.5 mg, with higher first-dose success rates (44.8% vs 25.3%), less need for additional atropine, and reduced need for rescue therapies 4. However, the established ACLS guidelines provide the 0.5 to 1 mg range as acceptable.

When to Use Atropine

Atropine is indicated for symptomatic bradycardia when the patient exhibits:

  • Hypotension (systolic BP <90 mmHg)
  • Altered mental status
  • Ischemic chest pain
  • Acute heart failure
  • Other signs of shock or poor perfusion 2

The bradycardia must be causing these symptoms—asymptomatic or minimally symptomatic patients generally do not require immediate treatment unless the rhythm is likely to progress (e.g., Mobitz type II in acute MI) 2.

Critical Caveats and Pitfalls

Atropine will likely fail or should be avoided in:

  1. Infranodal blocks (Mobitz type II, third-degree AV block with wide QRS): The block is below the AV node in the His-Purkinje system where vagal tone has minimal effect. Move directly to transcutaneous pacing or chronotropic infusions 3, 2

  2. Post-cardiac transplant patients: The denervated heart lacks vagal innervation, making atropine ineffective and potentially harmful—it may paradoxically cause high-degree AV block 1, 2, 5, 6

  3. Acute coronary ischemia/MI: Use cautiously—increasing heart rate may worsen ischemia or extend infarct size. Titrate to minimally effective heart rate (approximately 60 bpm) rather than aggressively normalizing 3, 2

Second-Line Options When Atropine Fails

If atropine is ineffective after full dosing (3 mg total):

Chronotropic infusions:

  • Epinephrine: 2 to 10 mcg/min IV infusion 1, 2
  • Dopamine: 5 to 20 mcg/kg/min IV infusion (start at 5 mcg/kg/min, increase by 5 mcg/kg/min every 2 minutes; doses >20 mcg/kg/min risk vasoconstriction and arrhythmias) 1, 2, 5, 6

Transcutaneous pacing: Should be considered when atropine fails, though evidence suggests it may not be more effective than second-line drug therapy 1, 2. It serves as a bridge to transvenous pacing in refractory cases.

Evidence Quality

The ACLS recommendations are based on one randomized trial and multiple observational studies showing atropine improves heart rate and symptoms in both in-hospital and out-of-hospital symptomatic bradycardia 1. The evidence is consistent across the 2010 International Consensus guidelines and 2010 AHA ACLS guidelines, with the 2019 ACC/AHA/HRS guidelines providing similar recommendations (Class IIa, Level of Evidence C-LD) 5, 6.

Approximately 50% of patients with hemodynamically unstable bradycardia respond to atropine (either partially or completely), with adverse responses being uncommon 7. Most patients who respond do so during the prehospital interval, and those requiring higher total doses or multiple doses are more likely to have AV block rather than sinus bradycardia 7.

References

Related Questions

What is the recommended initial intravenous dose of atropine for an adult patient presenting with shock and bradycardia?
What is the correct dosage and route for administering atropine to treat bradycardia in adults and children?
Which agent—atropine, epinephrine, dopamine, or isoprenaline (isoproterenol)—is preferred for managing unstable bradycardia when a pacemaker is unavailable, and what are the recommended dosing protocols?
What atropine dosing regimen should be used for patients with chronic liver disease who present with symptomatic bradycardia?
How should atropine be administered as an infusion for sinus bradycardia?
How long should I wait before switching from dofetilide (Tikosyn) to amiodarone?
What antibiotic regimen should be ordered to broaden coverage for a urinary tract infection beyond ceftriaxone?
What is the FRAX score, how is it calculated, and how does it guide osteoporosis management?
For an adult with moderate-to-severe alcohol use disorder who has failed standard therapies and has no history of psychotic disorder, uncontrolled hypertension, cardiac arrhythmia, or severe liver disease, is psychedelic‑assisted treatment (e.g., psilocybin, ibogaine, ayahuasca) appropriate, and what protocol and safety monitoring are recommended?
In an adult patient with normal quantitative glucose‑6‑phosphate dehydrogenase (G6PD) activity, what minimum hemoglobin level is required to safely initiate primaquine (0.25 mg/kg daily for 14 days) for radical cure of Plasmodium vivax or Plasmodium ovale malaria, and how should dosing be adjusted for hemoglobin between 8–10 g/dL?
In an adult patient with a proximal left anterior descending artery lesion and a fractional flow reserve of 0.8, what is the guideline-recommended revascularization approach?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.